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BACKGROUND: Peripheral arterial disease (PAD) is
undertreated by general practitioners (GPs). However,
the impact of the suboptimal clinical management is
unknown.
OBJECTIVE: To assess the mortality rate of PAD
patients in relation to the type of physician who
provides their care (GP or vascular specialist).
DESIGN: Prospective study.
SETTING: Primary care practice and academic vascular
laboratory.
PARTICIPANTS: GP patients (n = 60) were those of the
Peripheral Arteriopathy and Cardiovascular Events
study (PACE). Patients managed by specialists (n =82)
were consecutive subjects with established PAD who
were referred to our vascular laboratory during the
enrolment period of the PACE study.
MEASUREMENTS: All-cause and cardiovascular
mortality.
RESULTS: After 32 months of follow-up, specialist
management was associated with a lower rate of all-
cause mortality (RR=0.04; 95% CI 0.01–0.34; p =.003)
and cardiovascular mortality (RR=0.07; 95% CI 0.01–
0.65; p =.020), after adjustment for patients’ character-
istics. Specialists were more likely to use antiplatelet
agents (93% vs 73%, p <.001), statins (62% vs 25%,
p <.001) and beta blockers (28% vs 3%, p <.001).
Survival differences between specialists and GPs dis-
appeared once the use of pharmacotherapies was added
to the proportional hazard model. The fully adjusted
model showed that the use of statins was significantly
associatedwithareduced riskof all-causemortality(RR=
0.02; 95% CI 0.01–0.73, p =.034) and cardiovascular
mortality (RR=0.02; 95% CI 0.01–0.71, p =.033).
CONCLUSIONS: Specialist management of patients
with symptomatic PAD resulted in better survival than
generalist management. This effect appears to be
mainly caused by the more frequent use of effective
medicines by specialists.
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INTRODUCTION
Evidence suggests that specialists and generalist physicians have
different approaches to cardiovascular patients.
1–3 General practi-
tioners (GPs) provide care that is less resource-intensive and, thus,
potentially less expensive, but may be less aware of key diagnostic
and therapeutic advances. This may lead to worse outcomes.
1–3
General practitioners are the physicians primarily and largely
responsible for the diagnosis and treatment of patients with
symptomatic peripheral arterial disease (PAD), a condition
associated with high rates of ischemic events and increased
mortality.
4–6 However, there are indications that the awareness
and management of symptomatic PAD is unsatisfactory in
general practice. Indeed, although leg pain during walking can
be so troublesome as to adversely affect quality of life,
7,8 about
half the cases remain unrecognized.
9–11 Furthermore, in com-
munity-based office practice, PAD is undertreated in terms of
cardiovascular risk prevention.
10–12 It is worth noting that the
rate of aspirin therapy in patients with a cardiologist or
generalist as their main physician was 93% and 52%, respec-
tively.
12Unlessreferringtoacardiologistora vascular specialist,
theseundertreatedpatientswillpresumablyremainathighrisk.
Surprisingly, nothing is known about the outcome of PAD
patients managed by GPs versus the outcome of patients
managed by vascular specialists. This is particularly unfortu-
nate because such information would help health care author-
ities develop strategies to reduce morbidity and mortality in a
high-risk population.
To examine the mortality of patients with symptomatic
PAD in relation to the type of physician who provides their
care (GPs or vascular specialists), we compared the data of
patients of the Peripheral Arteriopathy and Cardiovascular
Events study (PACE),
10 who were managed by their GPs
(GP-PAD), with those of patients who were regularly moni-
tored by specialists at our vascular laboratory (S-PAD). We
also determined whether differences in outcome were
caused by PAD severity, prevalence of risk factors and other
comorbid illnesses, or to the use of drugs known to reduce
cardiovascular risk.
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639METHODS
We monitored 60 PAD patients managed by GPs, and 82 by
vascular specialists for a median of 32.0 (23.7–40.0) months.
Patients of both groups were enrolled in the study from
February 2002 to January 2003, and were at stage II of
Fontaines’ classification (i.e., intermittent claudication). No
patient of either group was in the terminal phases of severe
medical disorders. All 142 patients gave their informed
consent to the study, which was approved by the Ethics
Committee of our Institution.
Identification of Patients Managed by GPs. Algorithm of the
study is shown in Figure 1. In the PACE study, all subjects
aged 40–80 years, included in the lists of 7 GPs from 5 villages
of the Campania Region of Southern Italy, received a Rose
questionnaire.
10 To avoid that the different ways primary care
physicians diagnose and treat PAD patients could affect the
results, the 7 GPs who participated in the PACE study were
randomly selected from a group of 21. Symptomatic PAD was
suspected in subjects who at the questionnaire referred pain in
the calf, foot, thigh, or buttock (not in the knee) that began
while walking and did not disappear when they continued
walking, regardless of whether the remaining Rose criteria for
claudication were met. To confirm PAD diagnosis, “suspected”
symptomatic PAD cases underwent Doppler examination with
assessment of the ankle/brachial index (ABI) and flow velocity
in the femoral and posterior tibial arteries.
10 Symptomatic
PAD, defined by an ABI <0.90 or reduced flow velocity in at least
1leg,
13wasdiagnosed in60subjects.
10Baselinecharacteristics
wereobtainedfromthesubjects’electronic medicalrecords.The
software system, used by approximately 8,000 Italian GPs,
encodes all diagnostic records according tothe ninth edition of the
International Classification of Disease (ICD-9), and prescription
records according to the Anatomical Therapeutical Chemical
Classification system. Hypertension, hypercholesterolemia, and
diabetes mellitus were diagnosed with the criteria used in the
PACE study. After Doppler examination, all patients were
managed by their GPs. The diagnostic and therapeutic strategies
used by the GPs were not influenced by vascular specialists.
Prescription of cardiovascular therapies was checked at the first
visit and 6 months later.
Identification of Patients Managed by Vascular Specialists. To
identify patients undergoing specialist care, we evaluated all
consecutive subjects aged 40–80 years with suspected or
known PAD who were referred to our vascular laboratory.
Those with ABI <0.90 or reduced flow velocity in at least 1 leg
(i.e., the same criteria used in the PACE study) were enrolled in
the present study (n =82; Fig. 1). We obtained information
about cardiovascular risk factors and comorbidities from
hospital records and personal interviews during the first visit.
Figure 1. Algorithm of the study population.
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hypertension, hypercholesterolemia, and diabetes mellitus. All
S-PAD patients then underwent echo color Doppler scanning
of the abdominal aorta and the carotid arteries, according to
our routine protocol. S-PAD patients without symptoms or a
history of coronary artery disease (CAD) underwent
dipyridamole myocardial perfusion imaging (MPI) to verify the
presence or the absence of ischemic heart disease. After the
screening visits, cardiovascular medicines were prescribed
and compliance to treatment was checked at each follow-up
visit.
C-Reactive Protein Measurement. High-sensitivity C-reactive
protein (hs-CRP) plasma levels were measured by ELISA (Dade
Behring Diagnostics, Marburg, Germany).
Prospective Follow-up. We assessed all-cause mortality and
cardiovascular mortality, namely, death from myocardial
infarction, sudden death, or stroke. To obtain information
about deaths in the PACE cohort, every 6 months we reviewed
the patients’ electronic medical records, which were updated by
the GPs on the basis of hospital records and death certificates.
S-PAD patients were contacted for follow-up examination every
3 months. Mortality was documented by death certificates or
hospital records, which were reviewed by 2 cardiologists at our
department who were unaware of the aims of the study.
Statistical Analysis. Mortality rates were estimated by life table
curves, and differences in survival between GP-PAD and S-PAD
patients were calculated by the Wilcoxon test. Univariate and
age- and sex-adjusted Cox proportional hazard analyses were
used to evaluate the effect of being managed by a specialist on
survival. Cox analyses were also used to investigate whether
differences in survival between the GP-PAD and S-PAD groups
were affected by ABI, cardiovascular risk factors, previous
myocardial infarction, and previous stroke. We included
cardiovascular drugs in the proportional hazard models to
evaluate whether differences in drug use affected survival in
GP-PAD and S-PAD patients. To control for possible systematic
differences in the kinds of patients managed by specialists and
generalists, which would bias the comparison of mortality
rates, we first developed a logistic regression model with
specialist status of the attending physician as the dependent
variable.
14 This “propensity” model
15 included all the patient-
specific demographic and clinical data detailed above. The
propensity model was developed using the entire population,
and yielded for each patient the estimated probability of being
cared for by a specialist, expressed as a continuous variable
between 0 and 1. It can be shown that patients with the same
propensity score have the same distribution of the patient-
specific variables, regardless of whether they are managed by a
specialist or a generalist
15,16 (i.e., the propensity score is a
balancing score that controls for referral bias owing to the
observed variables). This score was then included in the
mortality models as an additional independent variable to
explicitly adjust for referral bias. Continuous variables are
expressed as mean±SD (normally distributed) or median and
25th and 75th percentile (nonnormally distributed). We used
the c
2 test, the t testfor unpaired samples, orthe Mann–Whitney
test as appropriate.
RESULTS
Baseline Characteristics. As Table 1 shows, patients managed
by specialists were younger and included a higher percent of
males. Therewere no statistical differences in classic riskfactors,
plasma levels of hs-CRP and ABI between the 2 groups. S-PAD
patients had a significantly higher prevalence of CAD and
previous myocardial infarction than GP-PAD patients.
Conversely, the prevalence of cerebrovascular disease and
previous stroke tended to be lower in S-PAD.
Medications and Cardiovascular Procedures. There were
pronounced differences in treatment between the 2 groups.
In fact, the rate of cardiovascular drug use was higher in S-PAD
patients. As Table 2 shows, the use of antiplatelet agents and
statins in S-PAD was about double that in GP-PAD (p <.001 for
both drugs). Beta blockers were used in a few patients in both
cohorts,butsignificantly lessoftenbyGPs (3% vs29%,p <.001).
Undertreatment of PAD by GPs is confirmed by the finding that
among hypertensives, 10 of 47 (21.3%) were untreated versus 4
of 66 (6.0%, p =.057) in S-PAD. Among hypercholesterolemic
subjects, 28 of 43 (65.1%) patients in the GP-PAD group were
untreated versus 14 of 57 (24.6%, p <.001) in the S-PAD group.
To evaluate whether the low rate of cardiovascular drug use in
the GP-PAD group was because GPs were unaware of the
presence of PAD, we checked cardiovascular drug prescriptions
6 months after thefirst visit (i.e.,whenPADhadbeenidentifiedin
cases previously unknown to the GPs). The cardiovascular
therapies remained substantially unchanged (Table 2).
Interventional therapies did not differ between the 2 groups.
The myocardial revascularization rate by cardiac artery by-pass
graft or percutaneous coronary intervention was 4% in S-PAD
patientsand5%inGP-PADpatients(p =.695).Thecorresponding
values for carotid surgery were 4% and 0% (p =.134).
With respect to diagnostic procedures, 29 S-PAD patients with
no symptoms or history of CAD underwent dipyridamole MPI.
Abnormal dipyridamole MPI was found in 4 (13.8%) patients who
Table 1. Baseline Characteristics of the Study Population
S-patients
(n =82)
GP-patients
(n =60)
P
ABI 0.65±0.16 0.63±0.15 .371
Risk factors
Age (yr) 64.8±10 69.0±8 .007
Males (%) 70 (85) 43 (72) .045
Ex-smokers (%) 42 (51) 22 (37) .101
Actual smokers (%) 33 (40) 15 (25) .067
Hypercholesterolemia (%) 57 (70) 43 (72) .786
Diabetes mellitus (%) 38 (46) 30 (50) .666
Hypertension (%) 66 (80) 47 (78) .753
Hs-CRP (mg/L) 2.8 (1.7–6.0) 3.4 (1.3–7.5) .550
Comorbidities
CAD (%) 48 (58) 20 (33) < .001
Previous MI (%) 34 (41) 7 (12) < .001
CVD (%) 12 (15) 16 (27) .067
Previous stroke (%) 2 (2) 3 (5) .402
S=specialist; GP=general practice; ABI=ankle/brachial index; hs-CRP=
high sensitivity C reactive protein; CAD=coronary artery disease; MI=
myocardial infarction; CVD=cerebrovascular disease
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electronic medical records at the first visit and during follow-up
showedthat no GP-PAD patient underwent dipyridamole MPI.All
S-PAD patients underwent echo color Doppler scanning of the
carotid arteriesand abdominalaorta. These 2 examinationswere
performed in only 19 (31.7%) and 1 (1.7%) GP-PAD patients,
respectively.
Outcome. Follow-up data were obtained for all 142 patients.
As Table 3 shows, there were 18 deaths: 4 (4.9%) in the S-PAD
group and 14 (23.3%) in the GP-PAD group. The corresponding
values for cardiovascular deaths were 2 (2.4%) and 10 (16.7%).
All-cause mortality and cardiovascular mortality were
significantly lower in S-PAD than in GP-PAD (p <.001 for
both endpoints) (Fig. 2). Crude and age- and sex-adjusted
analyses revealed that clinical outcome was significantly better
in S-PAD than in GP-PAD patients (Table 4). The survival of
patients managed by specialists was even better when the
statistical models were adjusted for ABI, risk factors,
cardiovascular comorbidities, and propensity scores (Table 4,
model 1).
Differences in treatment between specialists and GPs influ-
enced outcome. In fact, survival differences between S-PAD
and GP-PAD patients were no longer significant when the use
of statins, beta blockers, and antiplatelet agents was added to
the proportional hazard model (Table 4, model 2). However,
results changed when medication variables were added to the
models one at a time. The better survival in S-PAD versus GP-
PAD patients remained significant when either antiplatelet
agents or beta blockers were included in the analysis (results
not shown). Conversely, survival differences disappeared with
the addition of statins to the model. In fact, statins were
associated with a reduced risk of all-cause mortality (RR=0.02;
95% CI 0.01–0.73, p =.034) and cardiovascular mortality (RR=
0.02; 95% CI 0.01–0.71, p =.033).
DISCUSSION
We found that patients with symptomatic PAD treated by
vascular specialists had better outcomes than patients treated
by GPs. After adjusting for ABI, risk factors, and cardiovascu-
lar comorbidity (i.e., factors that can confound the association
between type of physician and survival, or known to be
associated with survival), GP-PAD patients continued to have
a greater incidence of both all-cause and cardiovascular death
than S-PAD patients.
Theoretically, our findings may be explained by at least 3
factors. The first is that differences in classical risk factors and
in plasma levels of hs-CRP, which is a marker of cardiovascular
risk in PAD,
17,18 led to lower mortality among patients managed
by specialists. However, adjustment for these confounders did
not account for the differences in survival. Secondly, differences
in mortality between S- and GP-PAD patients might be caused by
differences in PAD severity and in the prevalence of coexisting
cardiovascular disease. However, ABI, which is a sensitive index of
the severity of peripheral arterial insufficiency and a strong
predictor of cardiovascular risk,
6,19 was similar in the 2 cohorts.
Moreover, the prevalence of previous myocardial infarction was
over 3 times greater in S-PAD patients than in GP-PAD patients.
Even so, the incidence of death was about 4 times greater for GP-
PAD patients. In any case, the better survival associated with
specialist management remained after adjustment for previous
myocardial infarction and previous stroke. The greater prevalence
of previous myocardial infarction in the S-PAD cohort is consistent
with a report comparing patients from a vascular laboratory with
those from a general medicine practice.
20 This difference may be
because PAD patients with coexisting CAD are more likely to be
referred to specialists.
The third possibility is that specific aspects of care by
specialists were responsible for the better outcomes. Cardiol-
ogists and vascular specialists have more experience with
patients affected by cardiovascular disease, and more time to
devote to continuing education relevant to the treatment of this
condition. Consequently, they would be expected to be more
familiar than GPs with the diagnosis and management of PAD
and associated comorbidities such as coronary and carotid
artery disease. Indeed, PAD is a marker of generalized athero-
sclerosis,
21 and coronary and carotid arterial disease have
been documented also in PAD patients asymptomatic for
coronary and cerebrovascular disease. This is why PAD
patients referring to our vascular laboratory without a history
of CAD at the study entry undergo dipyridamole MPI, which
detects abnormal perfusion patterns in a high percentage of
PAD patients without a history or symptoms of CAD.
22 This
diagnostic approach was not used by GPs in their PAD
patients, as shown by a review of the electronic medical
records at the time of the first visit and during follow-up.
Similarly, all patients managed at our vascular laboratory
underwent echo color Doppler scanning of the carotid arteries
Table 3. All Cause Mortality and Cardiovascular Mortality
S-patients
(n =82)
GP-patients
(n =60)
All-cause mortality (%) 4 (4.9) 14 (23.3)
Cardiovascular mortality (%) 2 (2.4) 10 (16.7)
Sudden death (%) 0 (0) 2 (3.3)
Myocardial infarction (%) 1 (1.2) 4 (6.7)
Stroke (%) 0 (0) 4 (6.7)
Rupture of AAA (%) 1 (1.2) 0 (0)
S=specialist; GP=general practice; AAA=aneurysm of abdominal aorta.
Table 2. Use of Cardiovascular Drugs in the Study Population
S-patients (n =82) GP-patients (n =60)
At the
study
entry
At 6
month
follow-up
At the
study
entry
At 6
month
follow-up
P*
Beta
blockers
(%)
24 (29) 23 (28) 2 (3) 2 (3) <.001
ACE
inhibitors
(%)
41 (50) 43 (52) 26 (43) 26 (43) .432
Calcium
antagonists
(%)
38 (46) 38 (46) 33 (55) 33 (55) .308
Antiplatelets
(%)
76 (93) 76 (93) 35 (58) 37 (61) <.001
Statins (%) 49 (60) 51 (62) 12 (20) 15 (25) <.001
S=specialist; GP=generalpractice;p*referstocomparisonbetweenS-and
GP-patients at 6 month follow-up; ACE=angiotensin converting enzyme.
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able that asymptomatic coronary or carotid artery disease
went undiagnosed, and thus untreated in some GP-PAD
patients. Furthermore, specialists were more likely than GPs
to treat PAD patients with antiplatelet agents, beta blockers,
and statins, which reduce the cardiovascular risk in PAD.
23–26
We treated our PAD patients according to TransAtlantic Inter-
Society Consensus (TASC) recommendations,
27 which may not
be familiar to GPs. This may be caused by several factors.
First, the expanding body of research makes it difficult for a
generalist to be aware of every applicable guideline. Further-
more, physicians may not be able to overcome the inertia of
previous practice. Third, GPs are under great pressure from
health authorities to reduce costs, and this may lead to a
shortfall in the translation of knowledge to action. Indeed,
undertreatment of PAD by GPs is well recognized.
10–12 There-
fore, our finding of a better outcome associated with specia-
lists, and worse outcome associated with GPs, may be related
totheuse,orlackof use,ofappropriatecardiovasculartherapies.
Indeed, when the multivariate model was adjusted for these
therapies, the differences in mortality disappeared and statins
were significantly associated with better survival. This result,
coupled with that of a recent study on the effectiveness of cardiac
medications in PAD,
26 i n d i c a t e st h a tg r e a t e ru s eo fg u i d e l i n e -
supportedtherapies can lead tolowermortalityin these patients.
Study Limitations and Strengths. A major limitation of this study
is that patients were not assigned randomly to specialist or
generalist management. However, we used propensity analysis
and adjusted for known and possible confounding factors in
multivariate analysis. This procedure adjusts for selection
bias.
15 Moreover, ABI, the most sensitive prognostic indicator
in PAD, was similar in the 2 cohorts, and the 2 groups came
from the same geographic area, which rules out genetic,
ethnic, and lifestyle differences. Therefore, not surprisingly,
the prevalence of cardiovascular risk factors in S-PAD cohort
was similar to that in the GP-PAD cohort. The 2 populations
differed with respect to cardiac comorbidity. However, mortality
was greater among GP-PAD patients, although they had a
significantly lower prevalence of coexisting CAD and previous
myocardial infarction. Secondly, our results may not apply to
patients with asymptomatic PAD, who constitutes the majority
of PAD population. Furthermore, future studies are needed to
determine the generalizability of our findings to other countries.
Lastly, because patients receiving specialist care still have a
primary care provider, we cannot exclude that our results could
have been affected by an increased level of care (“additive effect”).
Figure 2. Survival curves in PAD patients managed by specialists (S-PAD, continuous line) and PAD patients managed by general
practitioners (GP-PAD, broken line). Left panel: all-cause mortality; right panel: cardiovascular mortality.
Table 4. Relative Risk (95% Confidence Interval) for All-cause and
Cardiovascular Mortality (Specialists Versus General Practitioners)
All-cause
mortality
P Cardiovascular
mortality
P
Univariate
analysis
0.17 (0.06–0.52) .002 0.11 (0.02–0.52) .005
Age–gender
adjusted
0.09 (0.02–0.41) .002 0.13 (0.03–0.62) .010
Multivariate
adjusted
Analysis
(model 1)
0.02 (0.01–0.28) .004 0.04 (0.01–0.60) .020
Multivariate
adjusted
Analysis
(model 2)
0.02 (0.01–1.53) .076 0.03 (0.01–5.62) .190
Model 1: adjusted for age, sex, ABI, smoking, diabetes mellitus,
hypercholesterolemia, hypertension, hs-CRP, previous myocardial infarc-
tion, previous stroke, and propensity scores.
Model 2: use of antiplatelet agents, beta blockers, and statins was added
to the covariates of model 1.
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in both cohorts, and follow-up information available for all 142
patients. Furthermore, the 7 GPs who participated in the PACE
study were randomly selected from a group of 21. Thus, the
different ways that primary care physicians diagnose and treat
patients with symptomatic PAD were well represented.
Conclusions. We found, in our study, that patients with
symptomatic PAD who were managed by vascular specialists
had a better survival rate than those managed by GPs. Based on
our data, it is conceivable that a greater useof pharmacotherapies
by specialists could contribute to survival advantage. Care by
specialists was also associated with the use of more cardiovascular
diagnostic procedures. In fact, it is well documented that PAD is
largely underdiagnosed and undertreated in GP.
10–12 Our data
indicate that this suboptimal clinical pattern may result in
increased mortality. Although the results of this study alone do
not justify a policy requiring that all patients with symptomatic
PAD be cared for by vascular specialists, they indicate a critical
need for an educational initiative directed at GPs to increase the
awareness of PAD, its consequences, and treatments effective in
improving survival of affected individuals.
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